These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Määtta M, Talvensaari-Mattila A, Turpeenniemi-Hujanen T, Santala M. Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443 [Abstract] [Full Text] [Related]
43. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P. Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957 [Abstract] [Full Text] [Related]
44. The relationship between matrix metalloproteinases (MMP-3, -8, -9) in serum and peripheral lymphocytes (CD8+ , CD56+ ) in Down syndrome children with gingivitis. Tsilingaridis G, Yucel-Lindberg T, Concha Quezada H, Modéer T. J Periodontal Res; 2014 Dec; 49(6):742-50. PubMed ID: 24372339 [Abstract] [Full Text] [Related]
46. Different circulating metalloproteinases profiles in women with migraine with and without aura. Martins-Oliveira A, Speciali JG, Dach F, Marcaccini AM, Gonçalves FM, Gerlach RF, Tanus-Santos JE. Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981 [Abstract] [Full Text] [Related]
47. Arterial obliteration in POEMS syndrome: possible role of vascular endothelial growth factor. Soubrier M, Guillon R, Dubost JJ, Serre AF, Ristori JM, Boyer L, Sauvezie B. J Rheumatol; 1998 Apr; 25(4):813-5. PubMed ID: 9558193 [Abstract] [Full Text] [Related]
48. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis. Lu LC, Yang CW, Hsieh WY, Chuang WH, Lin YC, Lin CS. Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243 [Abstract] [Full Text] [Related]
49. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes]. Florys B, Głowińska B, Urban M, Peczyńska J. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006 Dec; 12(3):184-9. PubMed ID: 17020653 [Abstract] [Full Text] [Related]
50. Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease. Kang HS, Kim JH, Phi JH, Kim YY, Kim JE, Wang KC, Cho BK, Kim SK. J Neurol Neurosurg Psychiatry; 2010 Jun; 81(6):673-8. PubMed ID: 19965844 [Abstract] [Full Text] [Related]
51. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S. Stroke; 2003 Sep; 34(9):2165-70. PubMed ID: 12907822 [Abstract] [Full Text] [Related]
56. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. Chen R, Zhang AR, Zhao XX, Li ZH. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606 [Abstract] [Full Text] [Related]
57. Serum levels of matrix metalloproteinases MMP-2 and MMP-9 and their inhibitors in women with glucose intolerance in pregnancy and normal controls. Stojanovic N, Lewandowski K, Salata I, Bienkiewicz M, Tuck S, Prelevic G, Press M. Gynecol Endocrinol; 2010 Mar; 26(3):201-7. PubMed ID: 19526397 [Abstract] [Full Text] [Related]
59. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. Zhang BB, Cai WM, Weng HL, Hu ZR, Lu J, Zheng M, Liu RH. World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082 [Abstract] [Full Text] [Related]